Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Acadia Healthcare Company Inc (ACHC) vs BioNano Genomics Inc (BNGO) Price & Performance

Acadia Healthcare Company Inc
BioNano Genomics Inc

Price performance

Price movement over the last 24 hours

Key statistics

Acadia Healthcare Company Inc vs BioNano Genomics Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.78 (market cap $2.94B), while BioNano Genomics Inc trades at $1.14 (market cap $13.08M). The key difference: Acadia Healthcare Company Inc is far larger — about 224.8× BioNano Genomics Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.

ACHCBNGO
Market Cap
$2.94B$13.08M
Sector
HealthHealth
52-Week High
$31.92$4.92
52-Week Low
$11.68$1.09
Enterprise Value
$5.45B$15.69M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Acadia Healthcare Company Inc

ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.

The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.

BioNano Genomics Inc

BNGO trades at $1.14, down 0.87% on the day, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 revenue of $28.51M and a net loss of $26.40M, though it beat EPS estimates. Recent news includes leadership changes, debt retirement, and growing adoption of its optical genome mapping technology. Valuation ratios appear low with a P/E of 0.03 and P/S of 0.3, but profitability remains negative.

Outlook is cautiously optimistic due to improving cash flow trends and analyst support, but significant risks persist from ongoing losses and competitive pressures. The stock's near-term direction hinges on achieving profitability and sustaining revenue growth amid high operational costs.

Returns comparison

Trailing returns across standard periods

About Acadia Healthcare Company Inc

Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.

Read more on ACHC

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO